Clinical Trials Logo

Clinical Trial Summary

Evaluation of Zepatier in a community-based setting among cirrhotic and non-cirrhotic patients on stable opiate substitution therapy.


Clinical Trial Description

Hard-to-reach groups such as those attending addiction and homeless services are particularly at risk for HCV-associated liver disease progression as they do not engage in treatment, have poor attendance records for appointments, and are at risk of progression to cirrhosis without evaluation and detection. These patients are therefore "silently" progressing in the community and may be close to decompensation. Once a patient goes over that critical stage from compensated to decompensated cirrhosis, the cost to the patient in terms of their health, and the cost to the state in terms of the management of cirrhosis related complications are great.

As part of this investigator-led community-based treatment protocol we aim to demonstrate the utility of an integrated community-based care partnership between primary and secondary care to best evaluate and treat such hard to reach populations.

We aim to actively find fibrosis levels of HCV related liver disease using the FibroScan diagnostic tool, and support patients to be treated for their HCV with the newly available DAAs and be cured of their HCV infection and disease through:

1. Active case finding by travelling to the services used by 'at risk' groups as opposed to giving appointments to the patient to attend hospital.

2. Locating HCV patients (with positive RNA or HCV antigen) that are 'lost to follow up'.

3. Staging and risk-stratifying HCV patients locally to support access to therapy.

4. Educating HCV patients around new assessment tools and treatments.

5. Setting up and supporting the initiation of treatment in the community e.g. daily dispensing of medication/treatment with methadone.

6. Providing on-going harm reduction advice on preventing reinfection.

7. Work in partnership with Methadone prescribing GP practices and Drug Treatment Centres from the North and South Dublin catchment area ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02895958
Study type Interventional
Source Mater Misericordiae University Hospital
Contact Jack Lambert, MD
Phone +353 (0)17164530
Email jlambert@mater.ie
Status Recruiting
Phase Phase 4
Start date March 15, 2018
Completion date January 2019

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT03413696 - Effects of Health Literacy and HCV Knowledge on HCV Treatment Willingness in HIV-coinfected Patients
Completed NCT01458054 - Effect of Omeprazole and Ritonavir on GSK2336805 Pharmacokinetics in Healthy Adults Phase 1
Recruiting NCT03426787 - Helping Empower Liver and Kidney Patients N/A
Completed NCT00006301 - Immune Response to Hepatitis C Virus
Not yet recruiting NCT03564639 - Examining Hepatitis C Reinfection Rates in Kenya
Not yet recruiting NCT03109457 - Hepatitis C Virus Detection in Oral Squamous Cell Carcinoma N/A
Recruiting NCT02961426 - Sofosbuvir Plus Ravidasvir for the Treatment of HCV Chronic Infection Phase 2/Phase 3
Recruiting NCT02683005 - Study of Hepatitis C Treatment During Pregnancy Phase 1
Active, not recruiting NCT02869776 - Integrating HCV and HIV Screening During the Era of HIV Antigen Testing N/A
Completed NCT02992184 - PoC-HCV Genedrive Viral Detection Assay Validation Study N/A
Completed NCT02705534 - Sofosbuvir, Ledipasvir, Ribavirin for Hepatitis C Cirrhotics, Genotype 1 Phase 3
Completed NCT03186313 - A Study to Evaluate the Safety and Efficacy of the Combined Single Dose of Dactavira Plus Or Dactavira in Egyptian Adults With Chronic Genotype 4 HCV Infection Phase 3
Recruiting NCT02393365 - Prevalence and Screening of Hepatitis C in Belgium in 2015 N/A
Completed NCT02596880 - Sofosbuvir, Daclatasvir, Ribavirin for Hepatitis C Virus (HCV) Cirrhotics Phase 3
Active, not recruiting NCT01962441 - SOF (Sovaldi®) +RBV for 16 or 24 Weeks and SOF+RBV+Peg-IFN for 12 Weeks in Adults With Genotype 2 or 3 Chronic HCV Infection Phase 3
Completed NCT01830205 - Pharmacokinetic and Safety Study of Daclatasvir in Patients With Renal Impairment Phase 1
Completed NCT01682720 - Sofosbuvir and Ribavirin in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection Phase 3
Completed NCT01445795 - Safety Study of INX-08189, Pharmacokinetic and Pharmacodynamic With Ribavirin and Food Effect Study, in Chronically-infected Genotype 1 Hepatitis C Virus, Treatment-naïve Subjects Phase 1/Phase 2
Completed NCT01441180 - GS-7977 With Ribavirin for Hepatitis C (SPARE) Phase 1/Phase 2
Completed NCT01389323 - BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis C Phase 3